



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Oxaliplatin (Eloxatin®) as Adjuvant Chemotherapy for  
Completely Resected Stage II and III Colon Cancer  
Capital District Health Authority/Cancer Care Nova Scotia**

**Approved Use:**

**Oxaliplatin:** In **combination with 5-FU/LV infusional based chemotherapy (FOLFOX)** as adjuvant therapy in patients who have documented evidence of **completely resected stage III colon cancer**, with an ECOG performance status of 0-2, for whom adjuvant chemotherapy would be recommended. A select group (PS 0-2) of **high risk patients with completely resected stage II colon cancer** should be considered for this therapy as well. This would include stage II patients with T4 lesions, inadequately sampled nodes, perforation or poorly differentiated histology for whom adjuvant chemotherapy may be recommended.

- This policy recommendation represents a **new guideline document** and a restriction of oxaliplatin to include completely resected stage III colon cancer patients and a select group of high risk completely resected stage II colon cancer patients.